# Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

> **NCT00224484** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5960 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **BIOLOGICAL:** GSK208141
- **BIOLOGICAL:** Havrix (investigational formulation)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00224484
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-07
- **Primary completion:** 2007-07-24
- **Final completion:** 2007-07-24
- **Target enrollment:** 5960 (ACTUAL)
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00224484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00224484, "Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00224484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*